2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1259

A Multi-Center Study for Validation of a New Assay for Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Autoantibody
Abstract Number: 933

A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients with Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results
Abstract Number: 2438

A Multi-Centre Survey of Tolerability Problems for Patients on Regular Methotrexate
Abstract Number: 1928

A Multicenter, Prospective Cohort Study Using Nailfold Videocapillaroscopy and Other Clinical Characteristics to Determine the Risk of Developing New Digital Ulcers in Patients with Systemic Sclerosis
Abstract Number: 928

A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthritis: Preliminary Data from 6,940 Patients
Abstract Number: 2443

A New Meta-Analysis on Safety of Ketoprofen Vs Ibuprofen and Diclofenac: Risk and Benefit of Nsaids Beyond Efficacy Meta-Analysis
Abstract Number: 1257

A New Multianalyte Assay for Detection of Dermatomyositis-Specific Autoantibodies Undetectable By Commercially Available Immunoassays
Abstract Number: 2077

A New Tender Point on the Plantar Arch in Primary Juvenile Fibromyalgia: A Potential Point to be Considered
Abstract Number: 2309

A Novel Approach to Assess Wait-Times to Rheumatologists
Abstract Number: 2691

A Novel CD123^–CD11c^– Dendritic Cell Subset Increased in Relation to Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 1951

A Novel CD27^(-) Spleen Tyrosine Kinase (Syk) Bright Memory B-Cell Subset Is Expanded in SLE
Abstract Number: 1132

A Novel Epigenetic Mark, Histone H1 Fucosylation, Orchestrates Macrophage Differentiation and Plasticity By Remodeling the Enhancer Landscape in Rheumatoid Arthritis
Abstract Number: 1886

A Novel Monocyte-Specific Transcript Underlies the Chromosome 21q22 Intergenic Genetic Association in Ankylosing Spondylitis
Abstract Number: 2796

A Novel Mouse Model of Osteochondromagenesis By Deleting NFATc1 in Mesenchymal Progenitors and Postnatal Chondrocytes
Abstract Number: 1940

A Novel Murine Model of B Cell-Mediated Glomerular Injury Is Mediated By Cytokines

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].